Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · VENMAX DRUGS AND PHARMACEUTICA · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
VENMAX DRUGS AND PHARMACEUTICA
BSE: 531015
BSE: 531015
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
VENMAX DRUGS AND PHARMACEUTICA
StateQ1 FY27 filed
Last close · 20 Sept 2026₹15.65
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA38.2 · 1.28 · 54.8
VENMAX DRUGS AND PHARMACEUTICA is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 8 |
| EBITDA (ex other income) | (0) | (0) | (0) | (1) | 0 |
| margin % | — | — | — | (131.3) | 1.5 |
| Owners' profit | 2 | 0 | 0 | (0) | 0 |
| EPS, as reported (₹) | 3.52 | 0.43 | 0.12 | 0.02 | 0.21 |
| ROE % · ROCE % | (196.4) · (197.4) | (31.6) · (31.8) | (9.9) · (13.5) | (0.2) · (0.3) | 1.8 · 2.0 |
| Debt / equity (x) | (0.37) | (0.49) | (0.54) | 0.01 | 0.02 |
| Cash from operations | 2 | (0) | 0 | (2) | (11) |
| Capex | 0 | 0 | 0 | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VENMAX DRUGS AND PHARMACEUTICA · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 2 |
| Profit before tax | (0) | (0) | 1 | 0 | 0 | 0 | 0 | 0 |
| Net profit | (0) | (0) | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | (0.58) | (0.95) | 1.49 | 0.07 | 0.05 | 0.05 | 0.21 | 0.10 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 38.2 | 29.6 | 107 of 170 | 37% |
| P/B | 1.3 | 3.3 | 33 of 164 | 80% |
| ROCE | 2.0 | 10.8 | 142 of 183 | 23% |
| ROE | 1.8 | 10.4 | 138 of 171 | 19% |
| Debt / Equity | 0.0 | 0.1 | 56 of 171 | 68% |
| EBITDA margin | 4.8 | 17.5 | 140 of 165 | 15% |
| Revenue growth | 104.9 | 16.3 | 9 of 161 | 95% |
| Profit growth | 211.8 | 30.9 | 22 of 158 | 87% |
| Market cap | 18 | 770 | 168 of 184 | 9% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VENMAX DRUGS AND PHARMACEUTICA · 22 September 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · NCLT orders shareholder meeting for Venmax Hatri Pharma merger | strategic transactions | medium | — | — |
| 1 Sept 2026 · Venmax Drugs submits FY26 Annual Report; AGM on September 26, 2026 | compliance | minimal | — | — |
| 31 Aug 2026 · Board approves 37th AGM notice, director changes and e-voting dates | results | high | — | — |
| 24 Aug 2026 · Board meeting on Aug 31 to approve 37th AGM notice and annual report | board shareholder meetings | low | — | — |
| 8 Aug 2026 · Newspaper publication of quarter ended June 30 2026 results | compliance | minimal | — | — |
| 7 Aug 2026 · Venmax Drugs: No deviation in preferential issue fund usage for Q1FY27 | compliance | minimal | — | — |
| 7 Aug 2026 · Q1 FY27 Results: Revenue doubles YoY; 7.8L warrants forfeited | results | high | — | — |
| 7 Aug 2026 · Q1 FY27 results: revenue up 105% YoY; board forfeits 7.8 lakh warrants | results | high | — | — |
| 1 Aug 2026 · Board meeting on Aug 7 to approve Q1 results and forfeit warrants | results | low | — | — |
| 30 Jul 2026 · 7,53,334 shares allotted on conversion of warrants | fund raising | medium | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in